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=Abstract=We describe a 9-year-old boy who showed typical neurologic manifestations i.e., 
progressive behavioral changes, intellectual impairment, visual disturbances and hearing loss, 
cerebellar and pyramidal signs with characteristic neuroimaging features, which led us to 
make a clinical deagnosis of ALD. It was confirmed later by demonstration of increased 
VLCFA levels in RBC membrane using HPLC. H e  has n o  family history of neurologic or 
endocrine disorder. Prophylactic antiepileptic medicaion could not prevent the development 
of seizure disorder. 
K e y  words: Adrenoleukodystrophy, Very long chain fatty acids, High-performance liquid chroma- 
tography, MR imaging. 
1983; Moser et a/. 1984). 
INTRODUCTION 
Adrenoleukodystrophy (ALD) is an X-linked re- 
cessive disease of childhood associated with 
rapidly progressive demyelination of cerebral 
white matter and varying degrees of adrenal cor- 
tical failure (Schaumburg et al. 1975). 
Most affected boys are between the ages of 5 
and '10 years when the first symptoms are 
noted; the initial clinical presentations are usually 
an alteration in behavior ranging from a with- 
drawn state to aggressive outbursts and intellec- 
tual impairment. Neurologic deterioration is then 
relentlessly progressive and includes loss of vi- 
sion and/or hearing, disturances of gait and coor- 
dination, long tract signs, and ultimate deteriora- 
tion to a vegetative state and finally death. Sei- 
zures are a late manifestation. Although the 
primary enzymatic defect in ALD is still un- 
known, recent investigations have disclosed that 
the metabolic defects occur in the oxidation of 
very long chain fatty acids (VLCFA) (Igarashi et 
a/. 1976; Moser et a/. 1981 ; Kobayashi et a/. 
CASE REPORT 
H.Y., a 9-year-old boy, was admitted to the 
Seoul National University Hospital because of 
progressive visual disturbance and hearing loss 
that had begun at 8 years of age. 
He was the first child of healthy young pa- 
rents. He had no family history of neurologic or 
endocrine disorder. Following an unremarkable 
pregnancy and delivery, he weighed 3.15 kg at 
birth. Growth and development milestones were 
normal. He appeared to be a bright child and 
was in perfect health until 8 months prior to 
study when he became poorly attentive and his 
school performance began to decline. Over the 
next few months, he developed a gait disturb- 
ance, dysarthria and drooling. 
His examination on admssion revealed a small 
wasted and somewhat dull-looking child. He 
was alert but expressionless. There was no 
abnormal skin pigmentation, and blood pressure 
was 90-100/60-70. Visual acuity was below 
0.0410.04, and visual f ield examination on 
penmetry revealed r~ght upper quadrant islands. 
Audiometry d~sclosed a bilateral sensorineural 
hearng loss (SNHL). Strength and sensations 
Fig. 1 .  a-d 
Non-contrast scans show areas of decreased attenuation In the deep w h ~ t e  mater (arrows) around the 
ventricular tr~gone (a,b). 
Contrast scan shows characteristic peripheral enhancement (E, arrow) (c,d). 
were normal, but he had spastic lower limbs. 
Tendon stretch reflexes were exaggerated with 
extensor plantar responses and sustained ankle 
clonus, bilaterally. He also showed bilateral dys- 
metria on finger to nose testing and showed 
spastlc awkward gait. Laboratory studies were 
as follows; normal hemogram and blood smear, 
urinalysis, calc~um 10.0 mg/100 ml, phosphorus 
5.0 mg1100 ml, and serum aspartate aminotrans- 
ferase (SGOT) 13 units. Metachromatic granule 
was negative in the urine. Serum cortisol was 
4.3 / ~ g / m l  in a morning sample and 20.3 , ~ g / m l  
in an evening sample. ACTH stimulation test re- 
vealed normal response. 
A Computed Tomography (CT) of the brain 
performed elsewhere demonstrated low density 
Fig 2 H ~ g h  f ~ e l d  strength MRI (2 0 Tesla) prec~sely show~ng  varlous levels pathways affected by d~sease ( S p ~ n  
Echo TR - 3,000 ms, TE - 80 msec) 
a Sect~on at the level of the pons shows d ~ s c r ~ t e  pyianlladl tract ~nvolvement (arrows) 
b MR lrnaqe at the level of m ~ d b r a ~ n  d~scloses c e r e ~ ~ ~ ~ ~ l  peduncle ~nvolvement (arrows) 
h MI? lrnage at  the level of frontal horns reveals ~nvolvernent of sp len~um of corpus callosurn and 
parleto occ~p~ td l  w h ~ t e  matter 
lesions of the subcortical w h ~ t e  matter adjacent 
t o  t he  vent r icu lar  t r lgone ,  ex tend ing  in to  
parieto-occipital areas (Fig.1 -a) with an enhanc- 
ing r im that  is more  p rominen t  anteriorly 
(Flg.1-b). A Magnetic Resonance lmaglng (MRI) 
scan (GS SPECTRO-20,000) revealed an area of 
high-intensity, symmetric, periventricular signal 
in the white matter of parletal lobes, discrete 
pyramidal tract involvement within the brainstem. 
lesions of the lateral cerbral peduncle and In- 
volvement of splenium of corpus callosurn 
(Fig.2). Electroencephalography (EEG) showed 
localized frontal slowing but no deflnite epileptl- 
form activity. After initial diagnostic work-up, he 
was put on an antiepillptic medication (Phenytoln 
200 mglday) to prevent possible selzure attacks. 
Two months after discharge, he developed a 
focal seizure with secondary generalization while 
his serum phenytoln level was maintained within 
the therapeutic ranges. On h ~ s  second admis- 
sion, all other cl~nical features got worse than 
before. His speech deteriorated almost to unln- 
telligibility. He could hardly walk out alone with- 
out assistance. 
On his third admission 6 months after in~tial 
diagnosis, he developed status epileptlcus. Dur- 
ing his last admission, for the analysis of VLCFA, 
venous blood was obtained with hepar~n-Na as 
an anticoagulant from the patient and the plasma 
and washed RBC's were prepared as suggested 
by Kobayshi et a1 (1983). The samples were 
stored at -60 C untll analyzed. Although the ac- 
tive seizure ceased, he could not regain his con- 
sclousness. The c h ~ l d  was discharged to the 
care of his parents in a vegetative state. 
DISCUSSION 
Adrenoleukodystrophy (ALD) refers to a group 
of degenerative disorders characterlzed by wide- 
spread demyelination and relentless neurological 
deterloration. Because the phenotype is varied, rt 
has been classified Into three maln subtypes; 
childhood ALD, adrenomyeloneuropathy (AMN) 
and neonatal ALD (Moser et a/. 1984). 
As previously mentioned, the most common 
childhood form IS distinguished by ~ t s  prom~nent 
cllnical features; slowly progresive behavioral 
changes, ~ntellectual impairment, loss of vision 
and/or hearing, cerebellar and pyramrdal slgns 
with or without evidence of adrenal lnsufficlency 
in a boy who has been in perfect health. 
Chi ldhood ALD and A M N  are f requent ly 
observed in the same kindred and have an 
X-linked hereditary trait. AMN usually does not 
begin until the second or thlrd decade or even 
later, and the disorder is characterized by adrenal 
lnsufflciency, variable hypogonadism, a slowly 
progressive demyelination in the splnal cord and 
in peripheral nerves that causes spastic para- 
paresis and distal polyneuropathy (Griffin et a/. 
1977). So it is now considered to be a more 
indolent variant of childhood ALD. Another form, 
neonatal ALD is now obviously different from 
childhood ALD, not only in inheritance pattern 
(autosomal recessive) but also in clinical man- 
ifestation; abnorml facial features, moderate to 
severe hypotonia, hepatomegaly and retinitis pig- 
mentosa (Moser et a/. 1980; Aubourg et a/. 
1 986). 
Because all neurological features were typicl 
of ALD, the clinical diagnosis was not so difficult 
in this patient, No family history of adrenal or 
neurologic disease could be elicited. 
After completing the initial diagnostic work- 
up, the boy was on prophylactic antiepileptic 
medication, but it was impossible to prevent, as 
might have been expected, the seizure attack 
caused by the progression of disease. 
Since lgarashi et a/. (1976) found abnormal 
accumulation of VLCFA in cholesterol ester frac- 
tions from cerebral white matter and adrenal 
glands of a patient with ALD, increased VLCFA 
levels have been found in other tissues and 
body fluids suggesting that ALD is a systemc 
metabolic disorder of this class of fatty acids 
(Igarashi et a/. 1976; Kobayashi et a/. 1983; 
Moser et a/. 1984; Rizzo et a/. 1984; Singh et a/. 
1 984). 
Although the specific enzymatic defects in 
ALD remain to be further established, studies 
showing impaired VLCFA oxidation in fibroblasts 
and leukocytes suggest that it is one of the 
peroxisomal disorders. Because of functional de- 
rangement in peroxisomes, where the /? -oxida- 
tion of fatty acids occurs, there results in accu- 
mulations of VLCFA in the tissues (Lazarow 
1987). The most consistently observed increase 
is that of hexacosanoic acid (C26:O) (Watkins et 
a/. 1987). Although typicl ALD shows clinical 
signs of adrenal failure such as cutaneous pig- 
mentation, hypotension or vomiting, drenal insuf- 
ficiency is not always clinically manifested. 
There are numerous reports of CT findings in 
ALD. The typical CT features, as seen in our 
patient, were large symmetric, low-density le- 
sions with peripheral enhancement that involved 
white matter of the occipital, posterior parietal, 
and temporal lobes (i.e., peritrigonal areas). Ex- 
tension of these lesions progressively involves 
the splenium of corpus callosum (Greenberg et 
a/. 1977; Chiro et a/. 1980; Aubourg and Diebler 
1982). However, atypical findings, i.e., front1 lobe 
involvement, predominantly unilateral involve- 
ment, calcifications within the white matter le- 
sion, and mass effect were also described (Chiro 
et a/. 1980; lnoue et a/. 1983). 
Recently a few reports have described MRI 
appearance of ALD and concluded that MRI is 
superior to CT in the demonstration of nervous 
system involvement (Bewermeyer et a/. 1985; 
Young et a/. 1983; Huckman et a/. 1986). Kumar 
et a/. (1987) described more detailed MR images 
in their six patients with ALD and suggested that 
MRI is the first imaging modality to demonstrate 
both auditory and visual pathway structural dis- 
ease in ALD. 
The present case certainly emphasizes the im- 
portance of the MRI. The scan obtained on the 
7th hospital day revealed discrete pyramidal tract 
involvement within the brainstem, involvement 
of auditory and visual pathways and extensive 
white matter lesion. These MRI findings are so 
characteristic that anyone can make diagnosis of 
ALD in a appropriate clinical settings. 
Open adrenal biopsy has been the most reli- 
able test for the diagnosis of ALD, but there 
have been a few autopsy proven cases with nor- 
mal adrenal function (Schaumburg et a/. 1975; 
Kim et a/. 1988). Lamellar inclusions observed in 
conjunctival or skin biopsies may help the di- 
agnosis but are still not confirmative (Arse- 
nio-Nunes et a/. 1981). 
Therefore, demonstration of increased hexaco- 
sanoic acid (C26:O) becomes indispensable for 
the confirmation of ALD, and it is possible to 
identify female carriers of ALD by verifying the 
increased plasma VLCFA level (Moser et a/. 
1983). Techniques for the prenatal diagnosis of 
ALD were also established (Moser et a/. 1982). 
In our case, the increased plasma VLCFA level 
was demonstrated using HPLC during the third 
hospital admission (Table 1). In an analysis of 
VLCFA the hexacosanoate (C26:O) was most 
notably increased. 
We're planning to measure the plasma VLCFA 
levels of this patient's mother and his younger 
sister. 
Recently some reports (Rizzo et a/. 1986; Au- 
bourg and Diebler 1982) have demonstrated that 
dietary restriction of C26:O with oleic acid sup- 
Table 1. Very long chain fatty acids of sphingomyelin 
in erythrocyte memberanes 
C 2 4 : O  C 25:O C 26:O 
---- --- 
Patlent 3.00 0.079 0.206 
Control 2.45 0.060 0.100 
(n=18) - +0.21 + 0.01 2 k 0.01 5 
Values are expressed on the basis of C 22:O. 
Control values are expressed as mean _+ SD. 
plementation lowers plasma VLCFA levels, but 
its clinical implication needs further refinement. 
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